AstraZeneca, Sanofi, AbbVie and Novartis will again face claims that they charged “unlawfully inflated prices” under the 340B drug discount program, after the case was dismissed in 2024.

On Tuesday, a federal appeals court revived …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844